Closely associated - generic antiepileptic drugs bioequivalence studies
Ended Indefinite Delivery Contract Awarded Last action
- Contract number
- HHSF223201210030I
- Awardee
-
Altasciences Clinical Kansas Inc. UEI WZ5RGEMMQ3W9
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Task orders
- 3 $3,204,946 obligated
Award facts
- Opportunity
-
- Bioequivalence Studies of Antiepileptic Drugs Award Notice · Posted Sep 27, 2012
- Bioequivalence Studies of Antiepileptic Drugs Award Notice · Posted Jun 27, 2012
- Combined order value
- $3,204,946 Current and potential, with all options
- Last date to order 100% complete
- IDV ceiling 64% used
- $5,000,000.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- NAICS code
- 541990 All Other Professional, Scientific, and Technical Services
- PSC
- B528 Special Studies/Analysis- Regulatory
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
Altasciences Clinical Kansas Inc. was awarded a single-award indefinite delivery contract from the Department of Health and Human Services Food and Drug Administration valued at up to $5 million. The contract aims to advance generic drug approvals through the conduct of bioequivalence studies and characterization of generic drugs.
Three firm fixed price delivery orders have been issued against this contract to date, with places of performance in Overland Park, Kansas. The first delivery order, issued in September 2015 for $983,066, was for a bioequivalence study of lamotrigine extended release tablets. The second, issued in September 2014 for $1,477,812, was for a bioequivalence and characterization study of generic drugs. The third, issued in September 2012 for $744,067, was for other functions related to generic antiepileptic drug bioequivalence studies.
The contract and associated delivery orders demonstrate the Food and Drug Administration's work to facilitate generic drug approvals and expand patient access to more affordable medications. Through clinical pharmacology studies conducted by Altasciences Clinical Kansas Inc., the agency aims to evaluate generic drug applications and support the development of safe and effective generic alternatives to branded medications.
Task orders
| Task order | Ordering agency | Obligated | Awarded |
|---|---|---|---|
| Project on bioequivalence study of lamotrigine extended release tablets. | Food and Drug Administration | $983,066 | |
| Study title bioequivalence and characterization of generic drugs. | Food and Drug Administration | $1,477,812 | |
| Other functions - generic antiepileptic drugs bioequivalence studies | Food and Drug Administration | $744,067 |
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract HHSF223201210030I?
HHSF223201210030I was awarded to Altasciences Clinical Kansas Inc. by Food and Drug Administration (Department of Health and Human Services) on September 14, 2012.
How much is contract HHSF223201210030I worth?
Orders under HHSF223201210030I have obligated $3,204,946. HHSF223201210030I's own ceiling is $5,000,000.
How many orders have been placed under contract HHSF223201210030I?
3 orders have been placed under HHSF223201210030I, the latest on September 10, 2015.
Who can order from contract HHSF223201210030I?
HHSF223201210030I is a single award indefinite delivery contract. Only the awarding agency can place orders on it.
Was contract HHSF223201210030I competed?
The extent of competition for HHSF223201210030I was full and open competition. The government received 1 offer.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV